NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PRPO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
management remains stable and executes turnaround plan | A supporting condition in Precipio Inc's published investment case. The stated target is management remains stable through 2026. | Intact | significant management turnover or disruption occurs | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making small-cap company with an emerging improvement story, rather than an established durable compounder. The long-term thesis is intact, but the evidence is limited and the next-quarter miss risk is elevated.
The snapshot describes PRPO as cheap versus peers, while also showing a 24% premium versus peers and low confidence in the valuation model. The expectations gap is strongly negative, and the priced-in assessment is tagged justified with low fragility, so the evidence does not point to a clearly strained set of expectations.
Near term, revenue growth and profitability progress are encouraging: Q2 revenue rose from Q1, Adjusted EBITDA turned positive, and operating income improved but remained negative. Management also reported positive operating cash flow and a higher cash balance than a year earlier, though cash generation remains a watch item and a recent quarterly miss raises the risk of another miss. Over the multi-year view, results depend on continued growth in pathology and products and progress toward sustained profitability.
A guidance cut on the next call or further weakening in jobs data could pressure the business outlook, especially given its cyclical exposure and elevated miss risk. Continued earnings strength and higher guidance from healthcare peers such as TMO, DHR, and NTRA would support the sector backdrop, but would not replace PRPO’s need to execute.
The 1-to-3-year thesis remains intact but uncertain: recent operating progress is real, while ongoing losses, limited evidence, and near-term execution risk remain important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Precipio Inc's published investment case. The stated target is reduce losses and move toward positive margins by FY26. |
| Improving |
| losses widen or margins fail to improve by FY26 |
Net margin: -3.12% FY2026-Q2; GAAP. Published target: reduce losses and move toward positive margins by FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-3.119214 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
annual revenue reaches at least $24 million in 2025 | Precipio is growing revenue with a target of at least $24 million in 2025. | Improving | annual revenue falls below $24 million in 2025 | Revenue: $7.021M FY2026-Q2; GAAP. Published target: >=24 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 20267,021,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.